- Home
- SLRX vs BDRX Comparison
SLRX vs BDRX Comparison
Compare SLRX & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLRX | BDRX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLRX | BDRX |
|---|---|---|
| Price | $0.67 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 303.7K | ★ 2.8M |
| Earning Date | 11-14-2025 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $2.22 |
| 52 Week High | $108.00 | $92.00 |
Technical Indicators
Market Signals| Indicator | SLRX | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.77 | 38.94 |
| Support Level | $0.62 | $2.22 |
| Resistance Level | $0.68 | $7.22 |
| Average True Range (ATR) | 0.05 | 0.71 |
| MACD | 0.06 | -0.22 |
| Stochastic Oscillator | 17.86 | 4.60 |
Price Performance
Historical ComparisonAbout SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.